Recently, IPR-179 (Act-03), a novel MMP2/MMP9-selective inhibitor, has been developed, which has antiseizure as well as antiepileptogenic effects and attenuates seizure-induced cognitive decline, without severe side effects, in two rodent models of epilepsy [156]. The gene discussed is MMP9; the disease is epilepsy.